Effect of Short-Term Oral Valproic Acid on Vision and Visual Field in Retinitis Pigmentosa
The aim of this study was to evaluate the effect of short-term oral valproic acid (VPA) on the vision and visual fields of patients with retinitis pigmentosa (RP).
In this prospective, nonrandomized trial, 10 patients (20 eyes) with established RP were treated with oral VPA 500 mg/day for 3 months. Visual acuity was monitored using the Snellen chart and values were converted into Early Treatment Diabetic Retinopathy Study chart and logarithm of the minimum angle of resolution (logMAR) equivalents. Visual field changes were evaluated using the Humphrey visual field analyzer (30-2 SITA standard test protocol).
Mean visual acuity was significantly improved from a pretreatment value of 20/72 (logMAR 0.560 ± 0.488) to 20/65 (logMAR 0.513 ± 0.422) after 3 months of treatment (P = 0.006). Vision improved by at least one line or more than one line in 10 eyes, and remained stable in the other 10 eyes. Visual field improvement was noted in nine eyes (P < 0.05, χ2 test), nine showing no significant field change and in two visual fields could not be recorded due to poor vision.
Short-term (3-month) treatment with VPA improves the vision and visual field of patients with RP.
- Clemson CM, Tzekov R, Krebs M, et al. Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011;95:89–93. CrossRef
- Van Schooneveld MJ, van den Born LI, van Genderen M, et al. The conclusions of Clemson et al. concerning valproic acid are premature. Br J Ophthalmol. 2011;95:153. CrossRef
- Sandberg MA, Rosner B, Weigel-DiFranco C, et al. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br J Ophthalmol. 2011;95:744. CrossRef
- Holladay JT. Proper method of calculating average visual acuity. J Refract Surg. 1997;13:388–91.
- Heijl A, Lindgren G, Olsson J, Asman P. Visual field interpretation with empiric probability maps. Arch Ophthalmol. 1989;107:204–8. CrossRef
- Leske MC, Heijl A, Hyman L, et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999;106:2144–53. CrossRef
- Heijl A, Leske MC, Bengtsson B, et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003;81:286–93. CrossRef
- Merin S, Obolensky A, Farber MD, et al. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther. 2008;24:80–6. CrossRef
- Berson EL, Rosner B, Weigel-DiFranco C, et al. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci. 2002;43:3027–36.
- Noorwez SM, Ostrov DA, McDowell JH, et al. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci. 2008;49:3224–30. CrossRef
- Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–78. CrossRef
- Massof R, Dagnelie G, Benzschawel T, et al. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vision Sci. 1990;5:1–26.
- Effect of Short-Term Oral Valproic Acid on Vision and Visual Field in Retinitis Pigmentosa
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Ophthalmology and Therapy
- Online Date
- November 2012
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- Retinitis pigmentosa
- Valproic acid
- Visual field
- Visual improvement
- Industry Sectors